{
  "ticker": "MYX",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02961606",
  "id": "02961606",
  "pages": 5,
  "price_sensitive": false,
  "date": "20250624",
  "time": "1755",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250624/pdf/06l22kyzjjx1wl.pdf",
  "summary": "### Material Information Summary (Change in Substantial Holding - Mayne Pharma Group Limited):  \n\n- **Substantial Holder**: UBS Group AG and related entities  \n- **Change Date**: 20 June 2025 (previous notice: 10 June 2025)  \n- **Voting Power Increase**:  \n  - Previous: 4,695,940 shares (5.78%)  \n  - Current: **5,808,252 shares (7.15%)**  \n- **Key Changes in Holdings (Appendix A)**:  \n  - UBS Securities Australia Ltd executed **multiple buys/sells** (net increase of ~1.1M shares).  \n  - **UBS Fund Management (Switzerland) AG** received **644,668 shares** as collateral on 20-Jun-25.  \n  - UBS AG London Branch reduced holdings by **50,000 shares** via rehypothecation returns.  \n\n**No capital structure impact or trading halt triggers identified.**  \n*Focus:* Monitoring UBS's increased stake for potential strategic intent (e.g., sponsoring capital raising, hedging).  \n\n*(Note: Detailed trades omitted; only aggregate impact is material.)*",
  "usage": {
    "prompt_tokens": 6714,
    "completion_tokens": 243,
    "total_tokens": 6957,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-06-24T08:27:14.127177"
}